Q BioMed Inc. (QBIO) Stock

About Q BioMed Inc.

Q BioMed Inc. functions as a biomedical accelerator and developer, actively licensing, acquiring, and supplying resources to firms within the life sciences and healthcare sectors. Its commercial portfolio includes Metastron (Strontium Chloride SR89), a radiopharmaceutical designed to alleviate pain associated with metastatic bone cancer. Additionally, Q BioMed is advancing a pipeline of therapeutic candidates, including Man-01, a pre-clinical compound aimed at primary open-angle glaucoma; QBM-001, intended for rare pediatric non-verbal autism spectrum disorder; and Uttroside-B, which targets liver cancer. The company also collaborates with Mannin Research Inc. on the development of treatments for conditions such as acute respiratory distress syndrome, glaucoma, and various kidney diseases. Incorporated in New York, New York, in 2013, the entity was initially named ISMO Tech Solutions, Inc. before adopting its current name, Q BioMed Inc., in July 2015.

Q BioMed Inc. (QBIO) stock trades at $0.00 with a market capitalization of $14509. The stock is valued at a price-to-earnings (P/E) ratio of 0.00, price-to-book of 0.00, price-to-sales of 0.05. Over the past 52 weeks the stock has ranged between $0.00 and $0.03, and currently trades 100.0% below its 52-week high.

On profitability, Q BioMed Inc. generates a return on equity (ROE) of 40.00% — well above the market average, a sign of a high-quality business, return on capital employed of 74.62%, a net profit margin of -721.67%.

Official website: www.qbiomed.com